On Nov 05, major Wall Street analysts update their ratings for $Inspire Medical Systems (INSP.US)$, with price targets ranging from $198 to $260.
Morgan Stanley analyst Kallum Titchmarsh maintains with a buy rating, and adjusts the target price from $210 to $230.
Wells Fargo analyst Larry Biegelsen maintains with a hold rating, and maintains the target price at $198.
Baird analyst David Rescott maintains with a buy rating, and adjusts the target price from $240 to $252.
KeyBanc analyst Brett Fishbin maintains with a buy rating.
RBC Capital analyst Shagun Singh Chadha maintains with a buy rating, and maintains the target price at $260.
Furthermore, according to the comprehensive report, the opinions of $Inspire Medical Systems (INSP.US)$'s main analysts recently are as follows:
The firm regards Inspire Medical as a top-tier selection following the company's recent financial performance, which included surpassing expectations for both revenue and earnings per share, along with a 33% increase in revenue growth and a 7% operating margin. Furthermore, the company's reaffirmation of its anticipated CNS revenue growth by FY25 was also highlighted.
Inspire Medical's third quarter sales and earnings per share exceeded expectations, leading to an increase in sales and earnings guidance for 2024. The fourth quarter sales forecast is somewhat more conservative, attributed to challenges such as hurricanes and intravenous supply shortages.
Here are the latest investment ratings and price targets for $Inspire Medical Systems (INSP.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.